Advertisement

Vascular Effects of Progestogens

  • Xiangyan Ruan
  • Alfred O. MueckEmail author
Chapter
Part of the ISGE Series book series (ISGE)

Abstract

Epidemiological, experimental, and biologic plausibility support a cardioprotective effect of estrogens in women. Indeed, women are protected until the menopause from the development of coronary artery disease and lag behind men in the incidence of myocardial infarction and sudden death by 20 years. Estradiol (E2) is implicated in this protective effect since at any age postmenopausal women have a greater cardiovascular risk than premenopausal and oophorectomized women not taking hormone replacement therapy (HRT).

Our knowledge regarding the vascular effects of progestogens mainly originates from studies using HRT. Progestogen effects, which are summarized in this review, were assessed according to clinical endpoints, metabolic effects, and influence on vascular markers in vitro or in vivo, respectively.

Keywords

Hormone therapy Cardiovascular protection Progestogens Vascular biochemical markers 

References

  1. 1.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–33.CrossRefGoogle Scholar
  2. 2.
    Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701–12.CrossRefGoogle Scholar
  3. 3.
    Schierbeck L. Primary prevention of cardiovascular disease with hormone replacement therapy. Climacteric. 2015;18:1–6.CrossRefGoogle Scholar
  4. 4.
    Manson JE, Aragaki AK, Rossouw JE, et al. (WHI Investigators). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA. 2017;318:927–38.CrossRefGoogle Scholar
  5. 5.
    Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161:249–60.CrossRefGoogle Scholar
  6. 6.
    Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374:1221–31.CrossRefGoogle Scholar
  7. 7.
    Lokkegaard E, Andreasen AH, Jacobsen RK, Lars Hougaard Nielsen LH, Carsten Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29:2660–8.CrossRefGoogle Scholar
  8. 8.
    Venetkoski MM, Savolainen-Peltonen HM, Rahkola-Soisalo PK, Hoti F, Vattulainen P, Gissler MVJ, Ylikorkala O, Mikkola TS. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause. 2017;25(4):375.  https://doi.org/10.1097/GME.0000000000001023.CrossRefGoogle Scholar
  9. 9.
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–11.CrossRefGoogle Scholar
  10. 10.
    Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci. 2002;966:143–57.CrossRefGoogle Scholar
  11. 11.
    Mueck AO, Seeger H. Estrogens acting as cardiovascular agents: direct vascular actions. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:35–42.CrossRefGoogle Scholar
  12. 12.
    Pang Y, Dong J, Thomas P. Progesterone increases nitric oxide synthesis in human vascular endothelial cells through activation of membrane progesterone receptor-α. Am J Physiol Endocrinol Metab. 2015;308:E899–911.CrossRefGoogle Scholar
  13. 13.
    Pang Y, Thomas P. Additive effects of low concentrations of estradiol-17β and progesterone on nitric oxide production by human vascular endothelial cells through shared signaling pathways. J Steroid Biochem Mol Biol. 2017;165:258–67.CrossRefGoogle Scholar
  14. 14.
    Yuan XH, Fan YY, Yang CR, Gao XR, Zhang LL, Hu Y, Wang YQ, Jun H. Progesterone amplifies oxidative stress signal and promotes NO production via H2O2 in mouse kidney arterial endothelial cells. J Steroid Biochem Mol Biol. 2016;155:104–11.CrossRefGoogle Scholar
  15. 15.
    Thomas P, Pang Y. Protective actions of progesterone in the cardiovascular system: potential role of membrane progesterone receptors (mPRs) in mediating rapid effects. Steroids. 2013;78:583–8.CrossRefGoogle Scholar
  16. 16.
    He Y, Gao Q, Han B, Zhu X, Zhu D, Tao J, Chen J, Xu Z. Progesterone suppressed vasoconstriction in human umbilical vein via reducing calcium entry. Steroids. 2016;108:118–25.CrossRefGoogle Scholar
  17. 17.
    Miller NR, Dolinsky BM, Napolitano PG. Micronized progesterone reduces vasoconstriction in the placenta. J Matern Fetal Neonatal Med. 2015;28:1581–4.CrossRefGoogle Scholar
  18. 18.
    Ramírez-Rosas MB, Cobos-Puc LE, Sánchez-López A, Gutiérrez-Lara EJ, Centurión D. Pharmacological characterization of the mechanisms involved in the vasorelaxation induced by progesterone and 17β-estradiol on isolated canine basilar and internal carotid arteries. Steroids. 2014;89:33–40.CrossRefGoogle Scholar
  19. 19.
    Baber RJ, Panay N, Fenton A. (on behalf of the IMS Writing Group). 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–50.CrossRefGoogle Scholar
  20. 20.
    Anggard E. Nitric oxide: mediator, murderer, and medicine. Lancet. 1994;343:1199–206.CrossRefGoogle Scholar
  21. 21.
    Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A–10A.CrossRefGoogle Scholar
  22. 22.
    Levin EL. Endothelins. New Engl J Med. 1995;333:356–63.CrossRefGoogle Scholar
  23. 23.
    Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001;47:403–11.PubMedGoogle Scholar
  24. 24.
    Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000;148:209–14.CrossRefGoogle Scholar
  25. 25.
    Chia MC. The role of adhesion molecules in atherosclerosis. Crit Rev Clin Lab Sci. 1998;35:573–602.CrossRefGoogle Scholar
  26. 26.
    Reape TJ, Groot TH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147:213–25.CrossRefGoogle Scholar
  27. 27.
    Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodelling and atherogenesis. Circ Res. 2002;90:251–62.CrossRefGoogle Scholar
  28. 28.
    Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:1792–801.CrossRefGoogle Scholar
  29. 29.
    Simoncini T, Caruso A, Girett MS, Scorticati C, Fu X-D, Garibaldi S, Baldacci C, Mannella P, Fornari L, Genazzani A. Effects of dydrogesterone and of its stable metabolite 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril. 2006;86(Suppl 3):1235–42.CrossRefGoogle Scholar
  30. 30.
    Mueck AO, Seeger H, Wallwiener D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause. 2002;9:273–81.CrossRefGoogle Scholar
  31. 31.
    Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 1999;100:717–22.CrossRefGoogle Scholar
  32. 32.
    Freudenberger T, Deenen R, Kretschmer I, Zimmermann A, Seiler LF, Mayer P, Heim HK, Köhrer K, Fischer JW. Synthetic gestagens exert differential effects on arterial thrombosis and aortic gene expression in ovariectomized apolipoprotein E-deficient mice. Br J Pharmacol. 2014;171:5032–48.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Ito F, Mori T, Takaoka O, Tanaka Y, Koshiba A, Tatsumi H, Iwasa K, Kitawaki J. Effects of drospirenone on adhesion molecule expression and monocyte adherence in human endothelial cells. Eur J Obstet Gynecol Reprod Biol. 2016;201:113–7.CrossRefGoogle Scholar
  34. 34.
    Seeger H, Kloosterboer HJ, Studen M, Wallwiener D, Mueck AO. In vitro effects of tibolone and its metabolites on human vascular coronary cells. Maturitas. 2007;58:42–9.CrossRefGoogle Scholar
  35. 35.
    Mueck AO, Seeger H, Deuringer FU, Wallwiener D. Effect of estrogen/statin combination on biochemical markers of endothelial function in human coronary cell cultures. Menopause. 2001;8:216–21.CrossRefGoogle Scholar
  36. 36.
    HERS Study Group. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/progestin Replacement Study. Circulation. 2002;105:2962–7.CrossRefGoogle Scholar
  37. 37.
    Berglind IA, Andersen M, Citarella A, Linder M, Sundstrom A, Kieler H. Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins. Menopause. 2014;22:369–76.CrossRefGoogle Scholar
  38. 38.
    Imthurn B, Rosselli M, Jaeger AW, Keller PJ, Dubey RK. Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab. 1997;82:388–94.PubMedGoogle Scholar
  39. 39.
    Rosselli M, Imthurn B, Keller PJ, Jackson EK, Dubey RK. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension. 1995;25:848–53.CrossRefGoogle Scholar
  40. 40.
    Ylikorkala O, Cacciatore B, Paakkari I, Tikkanen MJ, Viinika L, Toivonen J. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. Fertil Steril. 1998;69:883–8.CrossRefGoogle Scholar
  41. 41.
    Seeger H, Mueck AO, Teichmann AT, Lippert TH. Effect of sequential estrogen/progestin treatment on biochemical markers in postmenopausal women comparing oral and transdermal application. Clin Exp Obstet Gynecol. 2000;27:17–20.PubMedGoogle Scholar
  42. 42.
    Mueck AO, Seeger H, Lüdtke R, Gräser T, Wallwiener D. Effect on biochemical vasoactive markers during postmenopausal HRT: estradiol vs. estradiol/dienogest. Maturitas. 2001;38:305–13.CrossRefGoogle Scholar
  43. 43.
    Mueck AO, Ruan X, Seeger H, Hanke H. Vasodilative potency induced with Estradiol in women with and without CAD during standardized stress:- two paralyzed, randomized, double-blind, placebo-controlled cross-over studies. 18th World Congress of Gynecological Endocrinology, Florence (Italy), March 7th-10th 2018, Abstract ID 6616.Google Scholar

Copyright information

© International Society of Gynecological Endocrinology 2019

Authors and Affiliations

  1. 1.Beijing Obstetrics and Gynecology HospitalCapital Medical UniversityBeijingChina
  2. 2.Department of Women’s HealthUniversity Hospitals of TuebingenTuebingenGermany

Personalised recommendations